Parkinson’s Disease and Medical Cannabis: What Studies Show
Parkinson’s disease cannot be cured or slowed with medical cannabis, but some people with Parkinson’s use it for symptoms that their regular medicines leave behind: tremor, pain, anxiety and poor sleep. Here is what the research shows, how strong it is, and how a medical card works if you decide to talk to a physician about it.
- In people:
- surveys of people with Parkinson’s describe less tremor and fewer pain and anxiety pills with THC-heavier products, but these are self-reports, not trials [1][2].
- Only in the lab:
- cannabinoid compounds protected dopamine-making nerve cells in mice and in cell cultures; nothing like that has been shown in patients [3][4].
- With your doctor:
- any form, from capsules to drops, can add dizziness and sleepiness to your Parkinson’s medicines and change how some drugs are processed [5].
Built on peer-reviewed research published from 1981 to 2026: trials in people, surveys of patients, observational and laboratory studies.
Living with Parkinson’s when symptoms outpace treatment
The first years with Parkinson’s often go reasonably well. Levodopa works, the tremor quiets down, and daily life feels close to normal. Then the medicine starts to wear off before the next dose is due. Mornings begin stiff and slow, afternoons bring a “good window,” and evenings fall apart again.
To stretch the good hours, doses come closer together and new pills join the list: an agonist, an MAO-B inhibitor, something for sleep, something for constipation, something for low mood. Some people then get dyskinesia: restless, writhing movements that come from the medicine rather than the disease. Each fix seems to bring a new problem with it.
Much of what wears people down is not the tremor at all. It is the broken nights, the aching shoulder, the anxiety before leaving the house, the fatigue that sleep does not fix. These non-movement symptoms are real parts of Parkinson’s, and they are often the ones with the fewest good options.
Many people with Parkinson’s have asked themselves whether cannabis could help, and many hesitate to bring it up. They worry the neurologist will think less of them, or they picture a waiting room they would rather not sit in. That hesitation is understandable. The useful step is a calm conversation with a physician about adding an option alongside your treatment, never instead of it.
What wears on you most?
Pick one; you’ll see where this page covers it.
Choose a symptom above to see how it tends to change and where the evidence on it is discussed.
Tremor & stiffness: the resting tremor is usually the first thing others notice, and stiffness is often what limits you most. Both respond to dopamine medicines, but less fully as years pass. Tremor is the one movement symptom that patient surveys link to THC-heavier products; see what research says about each symptom.
Wearing-off & dyskinesia: as the brain loses its own dopamine, each dose lasts a shorter time, and higher doses can bring involuntary movements. No study on this page measured dyskinesia directly. Before anything is added, see interactions with Parkinson’s medicines.
Sleep: nights break up through stiffness, the need to urinate, vivid dreams and the medicine wearing off at 3 a.m. Sleepiness is a common cannabis side effect, but it is not the same as better sleep; see side effects and safety.
Pain: aching muscles, cramps in the “off” periods and shoulder pain are common and often under-treated. In one survey, people using THC-heavier products more often cut down a pain medicine [2]; see how big that effect is.
Anxiety & mood: anxiety often rises as a dose wears off, and depression is part of the disease itself, not only a reaction to it. Survey data on anxiety medicines are in the effect chart; mood risks are in who should be cautious.
Constipation & fatigue: both can start years before the diagnosis and tend to stay. Cannabis has not been studied for either in Parkinson’s, and drowsiness can make fatigue worse; see what science doesn’t know yet.
What is Parkinson’s disease?
Parkinson’s disease is a slowly progressive disorder of the brain. It begins when nerve cells in a small area called the substantia nigra, deep in the brain, gradually die. These cells make dopamine, a chemical messenger that the basal ganglia (the brain’s circuits for starting, scaling and smoothing movement) depend on. When dopamine runs low, movements become smaller, slower and stiffer, and a tremor can appear [6].
Inside the affected cells, a protein called alpha-synuclein misfolds and clumps into deposits known as Lewy bodies. The process is not limited to movement circuits: it also reaches nerves that control the gut, blood pressure, smell, sleep and mood, which is why many symptoms have nothing to do with movement [6].
Parkinson’s is common. About 500,000 Americans are diagnosed with it, and the real number is likely higher because many people go undiagnosed or are misdiagnosed. Most people are diagnosed at 60 or older, but an estimated 5 to 10 percent are diagnosed before 50 [7]. In most people there is no single cause: age is the strongest risk factor, and genes and environment each add some risk [7].
Standard treatment replaces or imitates dopamine. Levodopa (usually combined with carbidopa) is the most effective medicine; dopamine agonists such as pramipexole and ropinirole mimic dopamine; MAO-B inhibitors such as selegiline, rasagiline and safinamide slow its breakdown. Deep brain stimulation (DBS), a surgically implanted device, helps selected people with motor fluctuations. Physical therapy and exercise are part of care at every stage [6]. None of these stop the disease; they control symptoms, often well, for many years.
Parkinson’s disease
What it is: one specific disease, defined by loss of dopamine cells and Lewy bodies.
What causes it: mostly a mix of age, genes and environment; a few families carry single-gene forms.
What it tells you: the expected course, and that dopamine medicines usually work well.
Parkinsonism
What it is: an umbrella name for slowness, stiffness and tremor, whatever the cause.
What causes it: Parkinson’s disease, but also certain medicines, small strokes and rarer brain diseases.
What it tells you: that a neurologist still needs to find which cause it is.
Parkinson’s can also affect thinking. Over the years many people develop slower thinking, trouble with planning, and in some cases dementia. How fast this happens differs a great deal between people, and genes are part of the reason.
Quick answers
Is Parkinson’s genetic? Can it be inherited?
Mostly not in a simple way. A small share of people inherit a single gene change that causes Parkinson’s, often with an earlier start. Far more people carry variants that each add a little risk or shape how the disease progresses [7]. In the 2026 meta-analysis above, 7.9% of patients carried variants in the GBA1 gene and 17% carried the APOE e4 haplotype, and the more such progression variants a person had, the higher the risk of dementia (one variant: HR 1.56; two: HR 3.21) [8]. Having a parent with Parkinson’s raises your risk; it does not make the disease certain.
Can Parkinson’s disease be prevented?
No proven way exists. Regular physical activity is linked with lower risk and is recommended for everyone with Parkinson’s because it helps movement and mood. Nothing, cannabis included, has been shown to prevent the disease in people.
Is Parkinson’s disease rare?
No. With about half a million Americans diagnosed [7], it is one of the most common diseases of the aging brain, second among neurodegenerative diseases after Alzheimer’s. Onset before 50 is less common, but not rare.
Does Parkinson’s cause dementia or hallucinations?
It can. Thinking problems are part of the disease for many people, especially after many years, and genetics strongly shape that risk [8]. Hallucinations, usually seeing people or animals that are not there, can come from the disease itself or from dopamine medicines, and should always be reported to the neurologist. THC can also cause confusion and hallucinations, which is why people who already have them need extra caution.
Parkinson’s disease early symptoms and first signs
The best-known signs involve movement, but several non-movement symptoms can appear years earlier: a lost sense of smell, constipation, acting out dreams in sleep. Early signs usually start on one side of the body and creep in so slowly that family members notice them before the person does [6].
If you are wondering “could I have Parkinson’s?”, there is no self-test that answers it. The diagnosis is made by a doctor, ideally a neurologist, from a careful history and a physical exam; scans are used mainly to rule out other causes. The list below helps you describe what you notice; it does not tell you what it is.
Resting tremor
A rhythmic shake of a hand or finger at rest, often “pill-rolling,” that quiets when you use the hand.
studied in cannabinoid research
Slowness of movement
Doctors call it bradykinesia: buttons, typing and getting up from a chair take longer, and movements shrink as you repeat them.
Stiffness
Rigid muscles in the arm, neck or trunk, often felt as an aching shoulder long before anyone thinks of Parkinson’s.
Changes in walking
Shorter, shuffling steps, one arm that no longer swings, and a stooped posture that others notice first.
Smaller handwriting
Letters start normal and shrink across the line; the voice can also become softer and flatter.
Less facial expression
A “masked,” serious face and less blinking, often mistaken for low mood or tiredness.
Constipation
Slow bowels from the disease affecting gut nerves, sometimes many years before any tremor.
Loss of smell
Food tastes flat and smells go unnoticed; it is one of the earliest and most overlooked signs.
Sleep problems
Shouting or kicking while dreaming, broken nights and daytime sleepiness.
studied in cannabinoid research
Fatigue
A heavy, drained tiredness that rest does not fix and that often appears early.
Anxiety or low mood
New worry or flatness can be part of the disease itself, not only a reaction to it.
studied in cannabinoid research
Dizziness on standing
Blood pressure that drops when you stand up (orthostatic hypotension), with lightheadedness or near-fainting.
How does Parkinson’s disease progress, and is it fatal?
Parkinson’s usually progresses slowly, over many years and often over decades. Doctors describe early, middle and advanced stages, but the boundaries are blurry and people move through them at very different speeds: some stay in the early stage for a long time, while others change faster [7].
Is Parkinson’s fatal? The disease itself is not usually what ends a life. Most people with Parkinson’s live many years after diagnosis, and life expectancy for many is close to that of people without it. In the advanced stage, complications become the danger: falls that cause fractures or head injuries, and pneumonia when food or liquid slips into the lungs because swallowing has weakened (aspiration) [7]. That is why balance, swallowing and blood pressure deserve attention long before the late stage.
Can you keep working or driving? Often yes, for years, especially with a well-adjusted treatment plan and some flexibility at work. Driving depends on reaction time, attention and daytime sleepiness rather than on the diagnosis itself; a driving assessment can settle the question. Adding THC to the picture changes it, see driving and THC.
What are you watching most?
Pick one to follow it across the stages; nothing here tells you which stage you are in.
| Stage | Movement | Non-movement | Daily life | Treatment focus |
|---|---|---|---|---|
| Early | Tremor, slowness or stiffness on one side; mild changes in walking. studied in cannabinoid research | Loss of smell, constipation, dream enactment, low mood or anxiety. | Independent; most people keep working, driving and exercising. | Starting levodopa, an agonist or an MAO-B inhibitor; exercise and physical therapy. |
| Middle | Both sides affected; balance worsens; medicine “wears off” before the next dose; dyskinesia may appear. | Broken sleep, pain in “off” periods, fatigue, dizziness on standing. studied in cannabinoid research | Slower at tasks; first falls; work and driving may need changes. | Adjusting dose timing and adding medicines; DBS for some people. |
| Advanced | Freezing, frequent falls, may need a walker or wheelchair; swallowing becomes harder. | Thinking problems or dementia, hallucinations, marked blood pressure drops. | Needs help with daily activities; risk of aspiration pneumonia. | Comfort, safety and fewer sedating medicines; palliative and end-of-life care planning. |
The stage people search for most is the advanced one, and it is also where the body is most fragile. Any added medicine, cannabis included, then needs a physician’s eye on the whole list, because sleepiness and dizziness turn into falls more easily.
How Parkinson’s differs from Alzheimer’s and other look-alikes
Parkinson’s vs. Alzheimer’s, Lewy body dementia and Huntington’s
These diseases are often mentioned together because each affects the aging brain, and two of them share the same culprit protein. They start in different places, though, and cannabinoid research on each looks at different symptoms.
Compare with:
| Question | Parkinson’s | Alzheimer’s | Lewy body dementia | Huntington’s |
|---|---|---|---|---|
| What is affected | Dopamine cells in the substantia nigra; alpha-synuclein clumps | Memory areas first; amyloid plaques and tau tangles | Thinking areas early; the same alpha-synuclein as Parkinson’s | Deep movement circuits; caused by a single inherited gene |
| First signs | Tremor, slowness, stiffness; loss of smell | Forgetting recent events, repeating questions | Fluctuating alertness, visual hallucinations, then movement signs | Jerky, dance-like movements, mood and behavior changes |
| Course | Slow, over many years; thinking may decline later | Steady decline over years | Often faster than Alzheimer’s; very sensitive to some medicines | Progressive over many years, usually starting in midlife |
| What is known about cannabinoids | Patient surveys on tremor, pain and anxiety; lab work on protecting nerve cells | Small trials on agitation, sleep and appetite | Almost no data; THC may worsen hallucinations | Mostly preclinical work; human data are scarce |
Read more on Alzheimer’s disease and medical cannabis. Each of these conditions qualifies differently from state to state. Some lists name Parkinson’s, others name only some of the rest, so check how your state handles Parkinson’s.
Could medical cannabis be worth discussing for your Parkinson’s symptoms?
Fifteen short questions about your diagnosis, your hardest symptom and the medicines you take. Your answers stay on this page and show what to bring to a physician.
15 questions · about a minute · your answers stay in this browser
Cannabinoids, dopamine and neuroinflammation
Your body makes its own cannabis-like messengers, called endocannabinoids, and the receptors they act on. This endocannabinoid system is dense in the basal ganglia, the same movement circuits that lose dopamine in Parkinson’s, and it also helps regulate memory, emotion and the brain’s immune cells [9]. When dopamine falls, this system shifts too, which is one reason researchers became interested in cannabinoids such as THC and CBD.
The second reason is inflammation. In Parkinson’s, the brain’s immune cells (microglia) become persistently active around dying dopamine cells. Researchers suspect this “neuroinflammation” speeds the damage, and several cannabinoids calm these cells in laboratory models. Choose a target below to see what was found and in whom.
Where do cannabinoids act?
Choose a target above to see what each one does and how strong the evidence is.
CB1 receptor: the main brain target of THC, found throughout the basal ganglia, cortex and thalamus. In a 2026 brain-scan (PET) study of 23 people with Parkinson’s and 9 healthy volunteers, how many CB1 receptors were available was related to episodic memory and executive function [10].
CB2 receptor: sits mainly on immune cells, including microglia, and does not cause a “high.” In rat brain tissue and cultured cells, alpha-synuclein clumps increased the coupling of CB2 receptors with NMDA receptors, which carry the brain’s excitatory signals, suggesting a link between inflammation and nerve-cell stress [11].
PPAR-gamma: a switch inside cells that dampens inflammation. VCE-003.2, a compound derived from the cannabis molecule CBG, works through PPAR-gamma rather than CB1 or CB2; in mice it reduced activated microglia and protected dopamine cells [3].
Inflammasome (NLRP3): a protein complex that sets off inflammatory signals. In human-derived nerve cells exposed to two toxins used to model Parkinson’s, CBD-rich oil lowered NLRP3 protein by 49% and alpha-synuclein by 19.4% compared with the toxins alone [4]. Above 20 µg/mL, the same oil damaged the cells itself [4].
What does research say about cannabis for Parkinson’s symptoms?
Short answer: there are signals for a few symptoms, almost all from people describing their own experience, and no firm proof for any of them. Movement-disorder specialists who reviewed the evidence describe it as mixed: some patients report benefit, controlled trials have not settled the question, and side effects matter in this age group [1]. An older systematic review of cannabis trials across movement and neurodegenerative disorders reached no firm conclusion either [12].
That is useful to know before a conversation with a physician: it tells you what is reasonable to hope for and what is not. Choose a symptom to see what was tested, how strong it is, and what it means.
Tremor
Patient reports comparing products with more THC against products with similar THC and CBD [1].
Self-reported survey data; about 1.7 times the odds of reporting a better tremor with THC-heavier products [1].
The clearest signal on this page, and still not a trial result.
Stiffness & movement
In mice, the CBG-derived compound VCE-003.2 improved motor tests [3]. Trials of cannabis on movement in people have been small [12].
Animal data plus inconclusive human reviews.
No reason to expect cannabis to replace levodopa for slowness or stiffness.
Sleep
CBD lengthened sleep and changed daily rhythms in fruit flies; too much CBD over-prolonged sleep and blurred the day-night difference [13].
Insect data only; no sleep trial in people with Parkinson’s is cited here.
Feeling drowsy is not the same as sleeping better. Read whether cannabis is good or bad for sleep.
Pain
A web survey of people with Parkinson’s asked who had cut down or stopped a prescription pain medicine [2].
Self-report; those using THC-heavier products did so about twice as often as those using CBD-leaning ones [2].
A reason to ask, not proof; pain in “off” periods may need dose timing first.
Anxiety & mood
The same survey asked about anxiety medicines [2]; a separate review looked at CBD in psychiatric conditions outside Parkinson’s [5].
Self-report in Parkinson’s; mixed results and more side effects with THC [2].
“Higher risk, higher reward” was how the survey’s authors framed THC.
Dyskinesia
None of the studies cited on this page measured medicine-induced dyskinesia directly.
No usable data here.
An open question; dyskinesia is managed by adjusting Parkinson’s medicines with your neurologist.
How big is the effect?
Three results from people with Parkinson’s come with a range of likely values. All three compare people who used THC-heavier products with people who used CBD-leaning ones, and all three are what people reported about themselves.
How to read it: each dot is what people reported; the line around it is the likely range; the gray line means no difference. A dot to the right of the gray line means the outcome was reported more often with THC-heavier products.
People with Parkinson’s who used cannabis: THC-heavier products compared with CBD-leaning ones (self-reported)
- Tremor improved [1] 1.7× more often (1.17-2.57) [1]
- Cut down or stopped a pain medicine [2] 2.1× more often (1.57-2.83) [2]
- Cut down or stopped an anxiety medicine [2] 2.5× more often (1.79-3.56) [2]
Show as a table
| Outcome | Compared with | Odds ratio (95% CI) | Study |
|---|---|---|---|
| Tremor improved | Similar THC/CBD ratio | 1.7 (1.17-2.57), p = 0.01 | Review of patient survey data, 2024 [1] |
| Pain medicine decreased or stopped | Higher CBD | 2.11 (1.57-2.83) | Web survey, 2022 [2] |
| Anxiety medicine decreased or stopped | Higher CBD | 2.53 (1.79-3.56) | Web survey, 2022 [2] |
Can cannabis cure or slow Parkinson’s disease?
No. No study has shown that cannabis or any cannabinoid cures Parkinson’s disease, stops it, or slows it in people. The hopeful headlines come from experiments in mice and in cell cultures, and those are early steps that most often do not carry over to patients.
In mice and cells
VCE-003.2: given by mouth at 20 mg/kg for 14 days to mice with a Parkinson’s-like disease, this CBG-derived compound improved movement and preserved dopamine cells [3].
CBD and NLRP3: in nerve cells exposed to toxins, CBD-rich oil damped an inflammatory switch and reduced alpha-synuclein [4].
In people
Growth factors: a meta-analysis of human studies found no clear difference in blood levels of BDNF (SMD 0.26, 95% CI −0.34 to 0.76) or NGF (SMD −0.60, 95% CI −1.43 to 0.23), proteins that support nerve cells, between cannabis users and non-users [14].
Disease course: no trial in this research has measured whether cannabinoids change how fast Parkinson’s progresses.
Animal results do not transfer to people: the mouse model develops damage over weeks, not decades, and only male mice were used.
How the mouse study was done
Researchers used a virus to make mouse brain cells overproduce a mutant form of human alpha-synuclein (the A53T variant), which quickly damages dopamine cells. VCE-003.2 was given orally at 20 mg/kg a day for 14 days; about 69% of an oral dose reached the blood, peaking at about 4 hours [3].
Treated mice moved better and kept more dopamine cells. In the brain, the disease model changed the activity of 1,055 genes; treatment changed only 14, mostly in interferon (immune) signaling [3]. Alpha-synuclein levels were not reduced, the model is acute rather than slowly progressive, and only male mice were studied [3]. The authors call for human trials before any conclusion about patients.
What the research shows, from strongest to weakest
Not all studies count the same. A randomized trial, where people are assigned by chance to a cannabinoid or a placebo, can show cause and effect. A survey shows what people believe happened to them. A mouse study shows what is biologically possible. Here is what exists for Parkinson’s at each level.
| Level | What exists for Parkinson’s | What it can and cannot tell you |
|---|---|---|
| Trials and meta-analyses | Twelve randomized trials and seven meta-analyses in the published research on cannabinoids and Parkinson’s: few next to the reviews and lab studies; for example, the BDNF/NGF analysis [14]. | Best for cause and effect, but the trials are small and short, with results that point in different directions [1]. |
| Surveys and observational | Large patient surveys in the United States and France [2][15][16]; a provider survey [17]; a brain-scan study [10]. | Shows what people use and report; cannot separate real effect from expectation. |
| Animal and lab | Mouse, rat, fly and cell studies [3][18][11][19][13]. | Explains why scientists are interested; says nothing yet about patients. |
Browse the studies yourself
Every study cited on this page, in plain words. Neutral and negative results are included, and studies that are background rather than cannabis research are marked.
Genes that shape thinking decline in Parkinson’s
Across 24 cohorts and 28,737 clinic visits over 15 years, carrying more progression variants raised dementia risk step by step [8].
Cannabis use and nerve growth factors
No clear difference in blood BDNF or NGF between cannabis users and non-users; a neutral result [14].
Higher risk, higher reward?
People using THC-heavier products more often cut down pain and anxiety medicines, and also reported more side effects [2].
How people with Parkinson’s use cannabinoids
Patterns of use and self-reported effects; respondents reported only a minor impact on their other prescribed medicines [15].
Do clinicians accept cannabis for Parkinson’s?
91.3% supported easing legal limits on medical cannabis, yet 84.4% of physicians named missing official guidance and 77.8% the lack of evidence as barriers to CBD [17].
Natural health products alongside Parkinson’s medicines
Many patients use supplements for symptoms, and some herbs can interact with Parkinson’s drugs, for example St John’s wort with MAO-B inhibitors [20].
Cannabinoid receptors and memory in Parkinson’s
CB1 receptor availability was related to memory and executive function; small, with patients on their usual medicines [10].
What patients think of cannabis and CBD
Acceptability of and attitudes toward therapeutic cannabis and CBD among people with Parkinson’s [16].
Advice to people with Parkinson’s in my clinic: cannabis
Two movement-disorder specialists summarize the data as mixed, with the most consistent reports for tremor, pain and anxiety [1].
Medical cannabis in movement and neurodegenerative disorders
Trials across several disorders were inconclusive for Parkinson’s symptoms [12].
Cannabinoids in late-life Parkinson’s and dementia
Biological pathways look promising, but older adults face real clinical risks such as dizziness and sedation [21].
Phytocannabinoids in Parkinson’s and Alzheimer’s: lab evidence
A survey of recent preclinical work; useful as a map, not as proof for patients [22].
The endocannabinoid system in addiction and neurodegeneration
Explains how endocannabinoids shape the basal ganglia; conclusions remain open [9].
Brain spectroscopy to judge Parkinson’s treatments
Whether MR spectroscopy can track treatment effects; results were mixed [23].
CBD in mental health
CBD may interact with drugs processed by CYP3A4, CYP2C19, UGT1A9 and UGT2B7 enzymes; sedation and stomach upset were reported [5].
Pungent food compounds and the aging brain
Piperine from black pepper raised the absorption of curcumin, quercetin and some drugs, an example of how supplements change drug levels [24].
Palmitoylethanolamide and cognitive decline
A body-made fatty compound related to endocannabinoids, tested in animals and people with cognitive decline [25].
VCE-003.2 in a Parkinson’s-like mouse model
Better movement and preserved dopamine cells, without lower alpha-synuclein; male mice only [3].
CBD-rich oil and the NLRP3 inflammasome
Protected nerve cells from two toxins at low doses; toxic itself above 20 µg/mL [4].
CB2 and NMDA receptors in Parkinson’s
Alpha-synuclein clumps strengthened the CB2 – NMDA receptor link [11].
Mutant alpha-synuclein and dopamine signaling
Old mice made extra dopamine but had weaker signaling and 43.3% less CB1 binding in the substantia nigra [18].
CBD against a classic Parkinson’s toxin
CBD protected cultured cells from 6-OHDA through the Nrf2 antioxidant pathway [19].
CBD, sleep and daily rhythm in flies
CBD in food changed sleep and activity rhythms; too much CBD over-prolonged sleep [13].
Pharmacopuncture and Parkinson’s pain in mice
A herbal injection eased pain through CB1 and PPAR-gamma pathways; blocking either removed the effect [26].
No studies of this type are cited on this page.
What kinds of studies is this evidence built on?
How to read it: each row is one kind of study, and the bar shows how many published studies on cannabinoids and Parkinson’s are of that kind. Stronger designs are at the top. Gray bars are commentary, animal and lab work, which cannot answer whether something helps patients.
Show as a table
| Grouping | Kind of study | Studies |
|---|---|---|
| Design | Meta-analyses | 7 |
| Design | Systematic reviews | 6 |
| Design | Randomized trials | 12 |
| Design | Other clinical trials | 2 |
| Design | Cohort studies | 10 |
| Design | Case-control studies | 3 |
| Design | Cross-sectional studies | 7 |
| Design | Surveys | 10 |
| Design | Case reports | 4 |
| Design | Narrative reviews | 121 |
| Design | Animal studies | 47 |
| Design | Cell and lab studies | 14 |
| Who was studied | People in clinical trials | 24 |
| Who was studied | People observed, not treated | 235 |
| Who was studied | Whole populations | 9 |
| Who was studied | Animals | 26 |
| Who was studied | Cells and molecules | 21 |
| Who was studied | Research methods | 3 |
| Who was studied | Not classified | 64 |
CBD vs. THC for Parkinson’s: is there a best option?
There is no single best product for Parkinson’s. THC and CBD behave differently, the studies tested different products, and the right question is which balance, if any, fits your symptoms and medicines. In the patient surveys, THC-heavier products came with more reported benefit and more reported side effects at the same time [2]. CBD does not cause a “high,” but it is not inert: it can change how the liver handles other drugs [5].
Two very different things also share the word “cannabinoid.” Dispensary products are bought with a medical card. Prescription cannabinoids are FDA-reviewed medicines filled at a pharmacy with a regular prescription, and they are not the same as anything on a dispensary shelf.
| Product | What it is | What was studied | What came out |
|---|---|---|---|
| Dispensary products | |||
| THC-heavier | Products where THC, the intoxicating cannabinoid, dominates | Patient surveys on tremor, pain and anxiety [1][2] | More reported benefit and more side effects; self-report only |
| CBD-leaning | Products high in CBD with little THC; no “high” | Cell and fly studies; psychiatric reviews outside Parkinson’s [4][13][5] | Lab signals only for Parkinson’s; possible drug interactions in people |
| Balanced THC and CBD | Similar amounts of both | The comparison group in the tremor data [1] | Reported tremor improvement less often than THC-heavier products |
| Prescription medicines | |||
| Nabiximols | A THC and CBD mouth spray, approved in some countries outside the US | Psychiatric and neurological trials [5] | Sedation, decreased appetite and stomach upset were reported [5] |
| Nabilone | A synthetic THC-like capsule | Small trials, including in older adults [21] | Sedation and lethargy were almost three times more common than without it [21] |
| Dronabinol | A prescription THC capsule or liquid | Not tested for Parkinson’s in the studies on this page | No Parkinson’s data here |
| Epidiolex | Prescription CBD oral solution, approved for certain seizure disorders | Not tested for Parkinson’s in the studies on this page | No Parkinson’s data here; shares CBD’s interaction profile |
Forms of medical cannabis: what each avoids and what remains
Cannabis is not only smoked. People also vape it, swallow it as capsules, gummies or oils, hold drops under the tongue, or apply it to the skin. Each form avoids some risks and keeps others, and none of them is a safe default with Parkinson’s. This section explains the differences; it does not recommend a form, that choice belongs to the appointment.
How is it used, or how would it be?
Choose the closest; most people combine more than one.
Specific to smoking
Joints, blunts, pipes and bongs burn plant material, and the smoke irritates the throat and lungs, a real concern when swallowing and coughing are already weaker. The effect starts within minutes and is hard to measure. Lighting and holding a joint with a tremor is also a burn risk.
Specific to vaping and dabbing
Dry-herb vaporizers, oil pens and cartridges avoid burning, but hot vapor still travels the same airways. Concentrates used for dabbing, such as wax, shatter or rosin, are very strong, which makes the dose hard to control.
Shared devices
A pipe, vape or joint passed between people also passes on colds and other infections, and a chest infection is more serious in advanced Parkinson’s.
Specific to edibles and capsules
Gummies, chocolates, drinks, capsules and swallowed oils avoid smoke entirely. They act slowly, often an hour or more, last for hours, and pass through the liver before reaching the blood. The classic mistake is a second piece “because the first did nothing,” which then hits all at once; with a tendency to dizziness, that can end in a fall.
Specific to tinctures and sprays
Drops held under the tongue and mouth sprays avoid the lungs and are measured by the drop or spray. People who find swallowing pills hard sometimes ask about them; part of the dose is still swallowed, and the liver and interaction questions stay the same.
Specific to topicals and patches
Creams and balms act mainly where they are applied and do not reach brain symptoms. Transdermal patches are different: they deliver cannabinoids into the bloodstream, so their effects on the brain and on other medicines count the same as any other form.
Specific to prescription cannabinoids
Dronabinol, nabilone and Epidiolex have an exact dose and are prescribed by a doctor and filled at a pharmacy, not bought with a medical card. None is approved for Parkinson’s, and the THC-based ones carry the same drowsiness and fall risks as THC.
True of every form
- THC can cause sleepiness, dizziness and confusion, which raise the risk of falls.
- It can add to dizziness on standing caused by levodopa and dopamine agonists.
- Whatever reaches the blood is handled by the liver and can change levels of other drugs [5].
- No driving after THC.
Choosing a form is a conversation for the appointment.
All forms as a table
| Form | What it avoids | What remains |
|---|---|---|
| Smoking | Nothing in particular; fastest onset | Smoke in the airways, hard-to-measure dose, burn risk |
| Vaping and dabbing | Burning | Hot vapor in the airways; very strong concentrates |
| Edibles and capsules | Smoke and vapor | Slow, long effect; risk of a repeat dose; liver processing |
| Tinctures and sprays | The lungs | Part is swallowed; liver processing and interactions |
| Topicals | Effects on the brain | Skin reactions; no effect on brain symptoms |
| Patches | Lungs and stomach | Reaches the blood like other forms; same interactions |
| Prescription cannabinoids | Unknown product strength | Not approved for Parkinson’s; drowsiness with THC-based ones |
What science doesn’t know yet
Honest gaps are part of the answer. These are the limits the researchers themselves name, and they explain why no one can yet promise what cannabis will do for a particular person with Parkinson’s.
- Small groups. The brain-scan study of cannabinoid receptors had 23 patients; findings in groups that size can easily change [10].
- Snapshots, not stories. Cross-sectional studies and surveys capture one moment, so they cannot show cause and effect [10][17].
- Self-report. Patient surveys record what people believe changed, with no placebo group to compare against [2].
- Mice are not people. The mouse models damage dopamine cells over weeks, while human Parkinson’s unfolds over decades, and the transgenic models may not reflect the common form of the disease [3][18].
- Only male animals. Several animal studies used male mice only, so differences between men and women are unknown [3][26].
- Cells in a dish. The cell line used for the NLRP3 work does not behave like mature human dopamine neurons, and key confirmation tests were not done [4].
- Doses and the long run. There are no tested doses for Parkinson’s symptoms and no long-term data on falls, thinking or disease course with regular use.
- Who was studied. The large genetic analysis was mostly of people of European ancestry, so its risk estimates may not apply equally to everyone [8].
Side effects and safety for people with Parkinson’s
Side effects of cannabis overlap with symptoms Parkinson’s already brings: dizziness, sleepiness, unsteady balance, slower thinking. That overlap is the main safety issue, more than any single dramatic risk. The chart shows how often people reported each effect in two different groups.
How often did people report side effects?
How to read it: each bar is the share of people who reported that side effect, out of 100%; the number at the end is the exact share. Switch between the two groups: they were asked differently, so compare within a group, not across.
Show as a table
| Side effect | People with Parkinson’s (survey) | Older adults at a cannabis clinic |
|---|---|---|
| Dry mouth | 30.8% [2] | 7.1% [21] |
| Dizziness | 21.2% [2] | 9.7% [21] |
| Thinking or memory problems | 20.9% [2] | Not reported |
| More appetite or weight | 20.2% [2] | Not reported |
| Daytime sleepiness | 16.9% [2] | 3.9% [21] |
| Balance problems | 15.7% [2] | Not reported |
| Weakness | Not reported | 2.3% [21] |
| Nausea | Not reported | 2.2% [21] |
Across studies, sedation and lethargy were almost three times more common with nabilone, a prescription THC-like medicine [21]. Here is what each risk means with Parkinson’s.
Falls and balance
Parkinson’s already affects balance. Dizziness, sleepiness and slower reactions from THC add to it, and a fall can mean a broken hip.
Dizziness on standing
Orthostatic hypotension, a drop in blood pressure on standing, is common with Parkinson’s and its medicines; THC can deepen it.
Daytime sleepiness
Dopamine agonists can cause sudden sleep episodes. Sedating cannabis on top of them makes daytime dozing more likely.
Thinking and memory
About one in five survey respondents noticed thinking or memory problems [2]; this matters more if memory is already changing.
Hallucinations
Parkinson’s and its medicines can cause hallucinations; THC can add to them or bring confusion, especially later in the disease.
Driving
THC slows reaction time and judgment. Driving after use is unsafe and illegal in every state, card or not.
This page is an educational summary, not medical advice. Whether any of these risks outweighs a possible benefit for you is a decision for you and a physician who knows your full history.
Cannabis and Parkinson’s medications: interactions to discuss with your doctor
People with Parkinson’s usually take several medicines, often at exact times of day. Cannabinoids can matter in two ways. They can add to the effects of those medicines: dizziness, sleepiness, low blood pressure. And CBD can change how the liver breaks down some drugs: it should be used with caution alongside medicines processed by the CYP3A4 and CYP2C19 enzymes or by the UGT1A9 and UGT2B7 enzymes [5]. In a large French survey, people with Parkinson’s reported only a minor effect of cannabinoids on their other medicines [15] – reassuring, but a self-report, not a lab measurement.
Which of these do you take?
Choose all that apply; the matching notes open below. With nothing chosen, all of them stay listed.
Levodopa (carbidopa-levodopa) clinical
The main concern is added effects rather than a chemical clash: levodopa can lower blood pressure on standing and cause sleepiness, and THC can do both. Supplements matter too: velvet bean (Mucuna pruriens) contains natural L-dopa and can stack on top of your prescribed dose [20].
Ask your doctor: “Should I check my blood pressure lying and standing before and after trying anything new?”
Dopamine agonists (pramipexole, ropinirole, rotigotine) clinical
Agonists can cause sudden sleep episodes, low blood pressure, hallucinations and impulse-control problems. Sedating cannabis and THC-related confusion overlap with all of them.
Ask your doctor: “Given my agonist, would THC raise my risk of falling asleep during the day or of hallucinations?”
MAO-B inhibitors (selegiline, rasagiline, safinamide) pharmacokinetic
Herb-drug interactions with these medicines are documented; St John’s wort is the best-known example [20]. Cannabis products have not been studied with MAO-B inhibitors specifically, so the safe assumption is to list every product and supplement for your prescriber.
Ask your doctor: “Is anything I take, including supplements, a problem with my MAO-B inhibitor?”
Antidepressants pharmacokinetic
Several antidepressants are broken down by CYP2C19 or CYP3A4, the same enzymes CBD can slow [5]. Higher drug levels can mean more side effects. In the brain-scan study, some participants were also on escitalopram alongside their Parkinson’s medicines [10]. Mood itself can also swing with THC.
Ask your doctor: “Does CBD change the level of my antidepressant, and what would I notice if it did?”
Sleep aids and sedatives clinical
Benzodiazepines, sleeping pills, opioids and sedating antihistamines add drowsiness and unsteadiness to THC, and several of them are processed by CYP3A4 [5]. This is the combination most likely to end in a night-time fall. Read more on why mixing cannabis with Xanax is risky.
Ask your doctor: “If I try cannabis for sleep, which of my current sleep medicines should change?”
Several medicines at once mechanism only
Each extra medicine adds another possible interaction. Supplements count as well: black pepper extract (piperine), for example, raises blood levels of curcumin, quercetin and the seizure medicine carbamazepine [24] – a reminder that “natural” products change drug levels too.
Ask your doctor: “Can we review my whole list, prescriptions, supplements and anything I’m considering, in one sitting?”
Who should be cautious or avoid cannabis
For some people with Parkinson’s the risks clearly outweigh any possible benefit, or at least need a careful conversation first. This list is not filtered on purpose: read all of it.
- Psychosis or hallucinations, now or in the past, from the disease or from medicines: THC can bring them back or make them worse. Read more on psychosis and cannabis.
- Memory or thinking problems or dementia: THC can add confusion, and about one in five survey users noticed thinking problems [2].
- Frequent falls or poor balance: dizziness and sleepiness from THC raise the risk of a serious fall.
- Low blood pressure on standing: fainting spells or dizziness when getting up can get worse.
- Several sedating medicines: sleeping pills, benzodiazepines or opioids combined with THC deepen drowsiness.
- Pregnancy or breastfeeding: cannabis is not recommended, for any condition.
- Driving: anyone who still drives must not drive after THC.
Is Parkinson’s disease a qualifying condition for a medical card?
In many state medical marijuana programs, yes, but each state writes its own list, and the wording matters. Some name Parkinson’s disease outright. Others don’t name it but list symptoms it often brings, such as severe muscle spasms or chronic pain. A few leave room for a physician to certify other debilitating conditions. Your situation falls into one of three groups.
Parkinson’s is named in your state
The diagnosis in your records is usually enough for a physician to evaluate you. Bring the neurologist’s note.
A condition you also have is listed
Spasticity, chronic pain, insomnia or anxiety, if diagnosed and documented, may be the qualifying condition instead.
Neither is on the list
A card may not be available yet. Some states let physicians certify other debilitating conditions or accept petitions to add new ones.
What else has a doctor diagnosed?
State lists name diagnoses, not symptoms: pick what is in your records.
Choose a diagnosis above to see how it may count in your state.
Chronic pain: the most widely listed condition across state programs, and common in Parkinson’s. Read chronic pain and medical cannabis.
Muscle spasm: severe or persistent muscle spasms are on many lists and may describe painful cramps and rigidity. Read muscle spasms and medical cannabis.
Insomnia: a diagnosed sleep disorder is listed in some programs and often recorded alongside Parkinson’s. Read insomnia and medical cannabis.
Anxiety: several states list anxiety disorders or accept them under broader wording. Read anxiety and medical cannabis.
Depression: fewer states list it, and THC can affect mood in both directions. Read depression and medical cannabis.
Seizures: seizure disorders are on most lists. Read seizures and medical cannabis.
Nausea: some programs list severe nausea; levodopa can cause it in the first months. Read nausea and medical cannabis.
None of these: then the decision rests on your state’s wording and the physician’s judgment. Start with your state’s medical marijuana laws.
Parkinson’s disease by state: what to check
Four things differ from state to state, and each is set by the state program, not by us. Qualifying status: whether Parkinson’s is named, covered by a broader category, or left to the physician’s judgment. Possession limits: how much a patient may buy and carry at a time, usually higher than for adult-use buyers. Taxes: in several states patients skip part of the tax recreational buyers pay. Home cultivation: whether patients may grow a limited number of plants. Exact figures change with new laws, so we point you to the state rules rather than print numbers that may be out of date: medical marijuana laws by state.
Medical card or recreational purchase
In states with adult-use sales, adults can buy without a card. A card still changes several things, though the details are set state by state, and in a few states the difference is small.
| Aspect | With a medical card | Recreational |
|---|---|---|
| Taxes | Often lower; some states waive part of the cannabis tax for patients | Full state and local cannabis taxes |
| Possession limits | Usually higher | Lower, fixed by state law |
| Age | Adults 18 and older in most programs | 21 and older |
| Products | Access to medical dispensaries and, in some states, stronger products | Adult-use stores only |
| Legal standing | Recognized patient status under state law; some job and housing protections in some states | No patient status |
| Medical guidance | A physician reviews your diagnosis and medicines | None |
Will a card save you money?
Often, if you buy regularly in a state that taxes patients less than recreational buyers. The saving depends on your state’s tax rates, what you buy and how often, so it is different for every reader. These guides walk through the numbers: medical vs. recreational cannabis taxes and the difference between medical and recreational cannabis. In a state where the tax gap is small, the main reasons for a card are patient status, higher limits and a physician’s review of your medicines.
What the program in your state involves
After a physician certifies you, most states ask you to register with the state program; once approved, you buy from licensed medical dispensaries, and some states allow delivery. Many programs also let a patient who cannot easily get to a dispensary name a registered caregiver under state law, with rules on age and on how many patients one caregiver may serve. Cards are valid for a set period and need renewal. Whether your card works when you travel depends on the other state; see which states accept out-of-state medical cards.
Where are you starting from?
People come to this page from very different places. Choose the one closest to yours for the next step that fits it.
Choose your situation above to see your next step.
Just diagnosed: give yourself time to settle into treatment first; levodopa and exercise often work well early on. If symptoms like pain, sleep or anxiety stay hard, an evaluation is a reasonable next step. Start by reading what to bring to the appointment.
Renewing my card: start a few weeks before the expiry date; buying stops the day the card lapses. Tell the physician what changed since last time: new medicines, a DBS device, falls, how your symptoms responded. Your past records and documents are in your account and documents. Renewal guides by state:
Moved to another state: a card from your old state usually does not carry over; you register in the new one under its rules. Until then, see which states accept out-of-state cards.
Still working: many people with Parkinson’s work for years after diagnosis. Workplace protection for medical cannabis patients depends on your state and your job, and drug testing rules can still apply. Read the legal questions about work, driving and privacy first.
Lost my card: most states let you request a replacement through the state program, and your certification stays valid. Follow what to do if your medical card is lost, and find your documents in your account.
Legal questions: firearms, work, privacy and driving
A medical card protects you under your state’s law. It does not change federal law, and it does not override every rule an employer or another agency can set. These are the four questions people ask most.
Can I own or buy a gun with a medical card?
Federal law is the obstacle here. The federal firearms purchase form, ATF Form 4473, asks whether you are an unlawful user of marijuana and warns that marijuana use remains unlawful under federal law even where a state has legalized it for medical purposes [27]. Answering that question is your legal responsibility, so talk to a lawyer in your state before you apply for a card if firearms matter to you.
Will a card protect my job?
It depends on your state. Some states bar employers from firing or refusing to hire someone only for being a registered patient; others offer no such protection. Nowhere does a card allow you to be impaired at work, and jobs with federal rules, transportation, some government and safety-sensitive roles, can still test and act on a positive result.
Who can see that I am a patient?
Evaluations happen through telemedicine: a private online appointment with a physician licensed in your state, with nothing to travel to. Your medical records are protected health information under HIPAA, the federal health privacy law. State patient registries are confidential and are generally available only to the program, licensed dispensaries checking your status, and law enforcement verifying a card. Your employer and your neurologist are not told unless you tell them.
Can I drive with Parkinson’s and a medical card?
Many people with Parkinson’s still drive safely, and that decision rests on your reaction time, attention and daytime alertness. Driving under the influence of THC is illegal in every state, whether or not you have a card, and THC on top of Parkinson’s slowness and sleepiness makes it more dangerous. Keep cannabis in a sealed container in the trunk when you travel; more on traveling with medical cannabis.
What this means if you are considering it
If tremor, pain, sleep or anxiety are still hard despite good Parkinson’s care, asking a physician about medical cannabis is a reasonable step. Go in expecting a conversation about one or two symptoms, not a new treatment for the disease. Don’t be surprised if your neurologist is cautious: in a 2026 survey of providers who treat Parkinson’s, 84.4% of physicians named the absence of official recommendations and 77.8% the lack of evidence as barriers to CBD [17]. That caution is about the evidence, not about you.
What to bring to the appointment
Tap each item as you get it ready.
Questions worth asking
- Which of my symptoms could reasonably be helped, and which should be handled by adjusting my Parkinson’s medicines?
- Should I avoid THC, or keep it low, given my falls, blood pressure or memory?
- Does CBD change the levels of anything I take?
- What should make me stop and call you?
- How will we judge after a few weeks whether it is worth continuing?
An evaluation makes sense if
- a specific symptom stays hard despite treatment;
- your Parkinson’s medicines are stable;
- you are ready to share your full medicine list;
- you can keep your neurologist in the loop.
It is not the right step if
- you hope to slow or stop the disease;
- you plan to cut your Parkinson’s medicines;
- hallucinations or frequent falls are not yet assessed;
- you would need to drive soon after using it.
This page summarizes published research for education. It is not medical advice and does not replace your neurologist; any decision about cannabis is made with a licensed physician who knows your history.
How to get a medical marijuana card for Parkinson’s disease
Everything happens online, and you never need to sit in a waiting room. Here is what happens and when, so nothing comes as a surprise.
Tell us about your health
A short form about your diagnosis, symptoms and medicines. Have your medicine list handy.
See a licensed physician
A one-on-one appointment with a physician licensed in your state; you agree on the time with the doctor, so keep an hour free rather than a minute.
Get your signed recommendation
If the physician certifies you, the signed recommendation can be ready in as little as 15 minutes after the appointment, depending on your state.
Register with your state
Most states issue the card through their own program; review times are set by the state. Then you can buy at licensed dispensaries.
Can you go to a dispensary right after the appointment? In a few states the recommendation itself is enough; in most you wait for the state card. Your state page explains which applies. If the physician does not certify you, they will explain why and what they suggest instead.
What you end up with
Across 250 reviews from patients in the states where we are licensed. We do not sort them by score and do not hide the low ones.
- 150,000+patients evaluated – everyone who has been through an appointment with us, in every state where we are licensed
- Since 2017doing only this: online evaluations for medical cannabis programs, and nothing else on the side
Your recommendation and receipts stay in your account and documents. Learn how the online evaluation works and who our physicians are. Veterans can read about medical cards for veterans, and people on a tight budget about options for low-income patients.
Parkinson’s disease and medical cannabis: questions people ask
Does Parkinson’s disease kill you?
Parkinson’s itself is rarely the direct cause of death. In the advanced stage, complications such as falls and pneumonia from food or liquid entering the lungs are the main dangers [7]. Good care of balance, swallowing and blood pressure lowers those risks.
How long can you live with Parkinson’s disease?
Many people live for decades after diagnosis, and life expectancy for many is close to that of people without Parkinson’s. Age at diagnosis, other health problems and how the disease affects thinking and swallowing make the biggest difference.
How long does Parkinson’s disease take to progress?
Usually years to decades, at very different speeds from person to person. Genes are part of why: in a large 2026 analysis, people with more progression variants developed dementia far more often [8]. See the three stages.
Can Parkinson’s disease be cured?
Does Parkinson’s disease cause memory loss?
It can. Slower thinking and trouble with planning are common over time, and some people develop dementia. THC can add to memory problems: about one in five survey respondents with Parkinson’s reported thinking or memory problems with cannabis [2].
Does Parkinson’s disease cause constipation, fatigue or pain?
Yes, all three. Constipation can start years before movement symptoms, fatigue is common at every stage, and pain often comes with stiffness or “off” periods. Of the three, only pain has cannabis survey data in Parkinson’s [2].
Can you drive with Parkinson’s disease?
Often yes, especially early on; a driving assessment helps when in doubt. Driving after THC is illegal in every state and unsafe with Parkinson’s. See legal questions.
Is CBD good for Parkinson’s?
Is Parkinson’s disease a qualifying condition for medical marijuana?
In many states, yes, either by name or through a listed symptom such as muscle spasms or chronic pain. Lists differ by state; see how qualifying works.
Do I need a note from my neurologist?
Records of your diagnosis help a great deal, and a neurologist’s note or clinic letter is the simplest. The physician you see decides whether the documents are enough.
Is delta-8 the same as medical cannabis?
No. Delta-8 THC is usually made from hemp-derived CBD and sold outside medical programs, often without the testing medical products get. Its legal status varies by state; it is not part of a medical recommendation.
Does my card work in other states?
Some states accept out-of-state cards, many do not. Check which states accept out-of-state medical cards before you travel.
What if I lose my card?
Request a replacement through your state program; your certification stays valid. Steps are in what to do if your medical card is lost, and your documents are in your account.
More questions about medical cards · Health and wellness articles
More research on cannabis and Parkinson’s disease
This page cites a selection of studies. Our research library holds every study we track on cannabis and Parkinson’s disease, from laboratory work to clinical trials, and lets you filter them by cannabinoid, study type and year.
- studies
- 1,100+
- in people
- 370+
- clinical trials
- 30
Related brain and nervous system conditions
Qualifying lists differ by state, and many people with Parkinson’s also have a second diagnosis. These pages cover neighboring conditions in the same way.
Parkinson’s resources and latest research
New cannabinoid studies and changes to state programs appear every month. Start with how the endocannabinoid system works, browse health and wellness articles, or follow cannabis news for program changes in your state.
References
27 sources
- 1. Advice to People with Parkinson’s in My Clinic: Cannabis. DOI: 10.3233/JPD-230358 PMID: 38759024
- 2. Higher Risk, Higher Reward? Self-Reported Effects of Real-World Cannabis Use in Parkinson’s Disease. DOI: 10.1002/mdc3.13414 PMID: 35392299
- 3. Investigation in the cannabigerol derivative VCE-003.2 as a disease-modifying agent in a mouse model of experimental synucleinopathy. DOI: 10.1186/s12993-024-00256-9 PMID: 39487447
- 4. Cannabidiol Protects Against 1-Methyl-4-Phenylpyridinium and Manganese-Induced Neurotoxicity via Nod-Like Receptor Protein 3 Inflammasome Suppression. DOI: 10.1002/jbt.70957 PMID: 42262723
- 5. The therapeutic role of Cannabidiol in mental health: a systematic review. DOI: 10.1186/s42238-019-0012-y PMID: 33526132
- 6. National Institute on Aging. Parkinson’s Disease: Causes, Symptoms, and Treatments.
- 7. National Institute of Neurological Disorders and Stroke. Parkinson’s Disease: Challenges, Progress, and Promise.
- 8. Multi-locus genetic dosage shapes cognitive disease progression in Parkinson’s patients: 15-year meta-analysis of 24 cohorts. DOI: 10.1038/s41531-026-01367-y PMID: 42135313
- 9. From Synaptic Plasticity to Neurotoxicity: Endocannabinoid Influence on Addiction and Neurodegeneration. DOI: 10.3390/ijms262311632 PMID: 41373784
- 10. Deficits in episodic memory and executive functions in relation to CB1 receptor availability in Parkinson’s disease. DOI: 10.1177/1877718X261457830 PMID: 42351388
- 11. The Interplay Between CB2 and NMDA Receptors in Parkinson’s Disease. DOI: 10.3390/ijms26199419 PMID: 41096688
- 12. A Systematic Review of the Effectiveness of Medical Cannabis for Psychiatric, Movement and Neurodegenerative Disorders. DOI: 10.9758/cpn.2017.15.4.301 PMID: 29073741
- 13. Effects of cannabidiol to circadian period, sleep, life span, close-proximity rhythm, egg reproduction and motor function in Drosophila melanogaster. DOI: 10.1007/s10522-025-10305-z PMID: 40796675
- 14. Effect of cannabis use on blood levels of brain-derived neurotrophic factor (BDNF) and nerve growth factor (NGF): A systematic review and meta-analysis. DOI: 10.1002/brb3.3340 PMID: 38376038
- 15. Patterns of Use and Patient-Reported Effects of Cannabinoids in People With PD: A Nationwide Survey. DOI: 10.1155/padi/2979089 PMID: 40470397
- 16. Acceptability of and attitudes to the therapeutic use of cannabis and cannabidiol in people with Parkinson’s disease: A French survey. DOI: 10.1016/j.prdoa.2024.100286 PMID: 39687323
- 17. Healthcare Providers’ Acceptability of Cannabis And Cannabidiol to Manage Parkinson’s Disease in France. DOI: 10.1016/j.curtheres.2026.100830 PMID: 42095066
- 18. A53T-alpha-synuclein overexpression impairs dopamine signaling and striatal synaptic plasticity in old mice. DOI: 10.1371/journal.pone.0011464 PMID: 20628651
- 19. Cannabidiol Extracted from Cannabis sativa L. Plant Shows Neuroprotective Impacts Against 6-HODA-Induced Neurotoxicity via Nrf2 Signal Transduction Pathway. DOI: 10.5812/ijpr-160499 PMID: 40718446
- 20. Natural Health Products for Symptomatic Relief of Parkinson’s Disease: Prevalence, Interest, and Awareness. DOI: 10.3233/JPD-240102 PMID: 38943398
- 21. Cannabinoids in Late Life Parkinson’s Disease and Dementia: Biological Pathways and Clinical Challenges. DOI: 10.3390/brainsci12121596 PMID: 36552056
- 22. Recent Preclinical Evidence on Phytocannabinoids in Neurodegenerative Disorders: A Focus on Parkinson’s and Alzheimer’s Disease. DOI: 10.3390/ph18060890 PMID: 40573285
- 23. Using 1H-Magnetic Resonance Spectroscopy to Evaluate the Efficacy of Pharmacological Treatments in Parkinson’s Disease: A Systematic Review. DOI: 10.3390/ijms26199351 PMID: 41096620
- 24. Potential Protective Effects of Pungent Flavor Components in Neurodegenerative Diseases. DOI: 10.3390/molecules29235700 PMID: 39683859
- 25. Therapeutic effect of palmitoylethanolamide in cognitive decline: A systematic review and preliminary meta-analysis of preclinical and clinical evidence. DOI: 10.3389/fpsyt.2022.1038122 PMID: 36387000
- 26. SU-Eohyeol Pharmacopuncture Ameliorates Parkinson’s Disease-Associated Pain via the CB1 and PPARγ Pathways in an MPTP-Induced Mouse Model. DOI: 10.1155/prm/3334432 PMID: 42218674
- 27. Bureau of Alcohol, Tobacco, Firearms and Explosives. Firearms Transaction Record, ATF Form 4473.